Lapatinib is a kinase inhibitor indicated for the combination treatment of patients with advanced or metastatic breast cancer.
Medicince introduction including background, function, caution, etc.
Indication It is a member of the EGFR inhibitors drug class and is commonly used for Breast Cancer, and Breast Cancer – Metastatic.
SideEffects Inflamed mouth, digestive tract and airways mouth sores headache unusual hair loss or thinning
Mechanism Of Action It is an inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER-2 [ErbB2]) receptors.